LUNG DAMAGE IN RHEUMATOID ARTHRITIS - A PROSPECTIVE ANALYSIS
Abstract
The objective of this prospective study was to make correlations between demographic and rheumatoid arthritis (RA)-related characteristics and the type and severity of the interstitial lung involvement (ILD), being able to quantify a potential “gold standard” in predicting the development of these extra-articular manifestations (EAMs) that worsen the disease and increase the morbidity. Materials and methods: 60 RA patients were included in the analysis over a period of 2 years and the following data were centralized: demographic characteristics, the presence of lung damage quantified by pulmonary high-resolution computed tomography (HRCT), the presence of specific RA antibodies (anticitrullinated peptide antibodies - ACPAs), duration and activity of RA, pulmonary function measured by diffusing capacity for carbon monoxide (DLCO). Using different statistical tests, we analyzed the correlations between these parameters, trying to highlight the possible risk factors involved in the appearance of pulmonary manifestations in RA. Results: We included in our prospective study 60 patients, mostly women (n=46; 76.7%) with a mean age of 63.02±10 years old and with a mean age of disease onset of 51.89 years (95% CI: 48.86 to 54.93). Out of the 60 cases, data on smoking status was available for 34 participants, 82.4% being non-smokers, while 17.6% having an active smoker status. Regarding pulmonary function tests, 60% of the patients showed a decreased DLCO. More than half of the subjects (63.18%) had increased values of ACPAs. The results obtained were promising, demonstrating a direct relationship between both the DLCO decrease and the presence of specific ACPA antibodies, as well as between the appearance of lung-specific changes on HRCT and the increased titer of ACPAs. Also, the decrease in lung function was correlated with the radiological manifestations highlighted on HRCT. Conclusions: The presented study supports the close relationship between AR and ILD, pointing out the need for a careful pulmonary evaluation in these patients. The more active the disease, the higher the risk of developing lung damage. An early diagnosis and an adequate treatment can improve the prognosis of these patients.
References
1. Smolen JS, et al. Rheumatoid Arthritis. Nat Rev Dis Prim 2018; 4: 18001.
2. Cerro CG, Parimon T. Understanding Interstitial Lung Diseases Associated with Connective Tissue Disease (CTD-ILD): Genetics, Cellular Pathophysiology, and Biologic Drivers. Int J Mol Sci 2023; 24: 2405.
3. Ellman P, Ball RE. Rheumatoid disease with joint and pulmonary manifestations. Br Med J 1948; 2(4583): 816-820.
4. Chansakul T, Dellaripa PF, Doyle TJ, Madan R. Intra-thoracic rheumatoid arthritis: Imaging spectrum of typical findings and treatment related complications. Eur J Radiol 2015; 84(10): 1981-1991.
5. Bilgici A, Ulusoy H, Kuru O, Celenk C, Unsal M, Danaci M. Pulmonary involvement in rheumatoid arthritis. Rheumatol Int. 2005; 25(6): 429-435.
6. Solomon JJ, Brown KK. Rheumatoid arthritis-associated interstitial lung disease. Open Access Rheu-matology: Research and Reviews 2012; 5: 21-31.
7. Cavagna L, et al. The multifaceted Aspects of Interstitial lung disease in Rheumatoid arthritis. Biomed Res Int 2013; 2013: 759-760.
8. Nurmi HM, Purokivi MK, Karkkainen MS, Kettunen HP, Selander TA, Kaarteenaho RL. Variable course of disease of rheumatoid arthritis-associated usual interstitial pneumonia compared to other subtypes. BMC Pulm Med 2016; 16(1): 107.
9. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet 2016; 388: 2023-2038.
10. Hallowell RW, Horton MR. Interstitial lung disease in patients with rheumatoid arthritis: spontaneous and drug induced. Drugs 2014; 74: 443-450.
11. Mori S, Koga Y, Sugimoto M. Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Respiratory medicine 2012; 106(11): 1591-1599.
12. Chetta A, et al. Relationship between outcome measures of six-minute walk test and baseline lung function in patients with interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18(2): 170-175.
13. Zhang M, Yin J, Zhang X. Factors associated with interstitial lung disease in patients with rheumatoid arthritis: A systematic review and meta-analysis. PLoS ONE 2023; 18: e0286191.
14. Matson SM, Demoruelle MK, Castro M. Airway Disease in Rheumatoid Arthritis. Ann Am Thorac Soc 2022; 19, 343-352.
15. Spagnolo P, Lee JS, Sverzellati N, Rossi G, Cottin V. The Lung in Rheumatoid Arthritis: Focus on Interstitial Lung Disease. Arthritis Rheumatol 2018; 70: 1544-1554.
16. Wang D, et al. Mechanisms of lung disease development in rheumatoid arthritis. Nat Rev Rheumatol 2019; 15: 581-596.
17. Klester E, et al. Risk factors of interstitial lung diseases in patients with rheumatoid arthritis. Eur Respir Soc 2019; 54: PA1365.
18. Chen N, Diao CY, Gao J, Zhao DB. Risk factors for the progression of rheumatoid arthritis-related interstitial lung disease: Clinical features, biomarkers, and treatment options. Semin. Arthritis Rheum 2022; 55: 152004.
19. Wang T, Zheng XJ, Liang BM, Liang ZA. Clinical features of rheumatoid arthritis associated interstitial lung disease. Scientific Reports 2015; 5(1): 14897.
20. Radovits BJ, Fransen J, Al Shamma S, Eijsbouts AM, van Riel PL, Laan RF. Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010; 62(3): 362-370.
21. Gabriel SE et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003; 48(1): 54-58.
22. Young A, et al. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischemic heart disease and in pulmonary fibrosis. Rheumatology 2007; 46(2): 350-357.
23. Tsuchiya Y, et al. Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Euro Respir J 2011; 37(6): 1411-1417.
24. Avnon LS, et al. Pulmonary functions testing in patients with rheumatoid arthritis. Isr Med Assoc J 2009; 11(2): 83-87.
25. Zrour SH, et al. Correlations between high-resolution computed tomography of the chest and clinical function in patients with rheumatoid arthritis. Prospective study in 75 patients. Joint Bone Spine 2005; 72(1): 41-47.
26. Biederer J, Schnabel A, Muhle C, Gross WL, Heller M, Reuter M. Correlation between HRCT find-ings, pulmonary function tests and bronchoalveolar lavage cytology in interstitial lung disease associ-ated with rheumatoid arthritis. Eur Radiol 2004; 14(2): 272-280.
27. Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR. Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis. Ann Rheum Dis 2002; 61(6): 517-521.
28. Mena-Vázquez N, et al. Analysis of clinical-analytical characteristics in patients with rheumatoid arthritis and interstitial lung disease: Case-control study. Reumatología Clínica (English Edition) 2021; 17(4): 197-202.
29. Doyle TJ, et al. Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum bi-omarkers. Am J Respir Crit Care Med 2015; 191: 1403-1412.
30. Kelly CA, et al. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics-a large multicenter UK study. Rheumatology (Ox-ford). 2014; 53: 1676-1682.
31. Aubart F, et al. High levels of anti-cyclic citrullinated peptide autoantibodies are associated with co-occurrence of pulmonary diseases with rheumatoid arthritis. J Rheumatol 2011; 38: 979-982.
32. Zhang Y, Li H, Wu N, Dong X, Zheng Y. Retrospective study of the characteristics and risk factors of rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol 2017; 36: 817-823.
33. Kim EJ et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. European Respiratory Journal 2010; 35(6): 1322-1328.
34. Fu Q, Wang L, Li L, Li Y, Liu R, Zheng Y. Risk factors for progression and prognosis of rheumatoid arthritis-associated interstitial lung disease: single center study with a large sample of Chinese popu-lation. Clinical rheumatology 2019; 38: 1109-1116.
35. Samy N, Salah H, Hammoda RM. Rheumatoid arthritis patients with interstitial lung disease: clinical, radiological and laboratory characteristics. The Egyptian Rheumatologist 2021; 43(1): 29-34.
36. Paulin F, et al. Lung involvement prevalence in patients with early rheumatoid arthritis without known pulmonary disease: a multicentric cross sectional study. Advances in Rheumatology 2021; 61: 52.
37. Oak J, Sharma S, Shastri R, Singh S. Interstitial Lung Disease in Rheumatoid Arthritis: A Prospective Study at a Tertiary Care Center. Indian J Chest Dis Allied Sci 2022; 64(3): 168-172.
38. Bessa EJ, et al. Association between clinical, serological, functional and radiological findings and ventilatory distribution heterogeneity in patients with rheumatoid arthritis. PLoS ONE 2023; 18(10): e0291659.

Additional Files
Published
Issue
Section
License
Copyright (c) 2024 The Medical-Surgical Journal

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
COPYRIGHT
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.
COPYRIGHT TRANSFER FORM FOR
REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /
THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI
We, the undersigned authors of the manuscript entitled
_____________________________________________________________________________________
_____________________________________________________________________________________
warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.
- we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
- the manuscript does not break the intellectual property rights of any other person.
- we have read the submitted version of the manuscript and we are fully responsible for the content.
Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):
- ______________________________/_________________________
- ______________________________/_________________________
- ______________________________/_________________________
N.B. All the authors must sign this form